Carcinoma de células renales

Referencias

Artículos principales

American Urological Association. Renal mass and localized renal cancer: evaluation, management, and follow up. 2021 [internet publication].Texto completo

Warren AY, Harrison D. WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World J Urol. 2018 Dec;36(12):1913-26.Texto completo  Resumen

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2019 May;30(5):706-20.Texto completo  Resumen

European Association of Urology. Renal cell carcinoma. 2021 [internet publication].Texto completo

Rini BI, Battle D, Figlin RA, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019 Dec 20;7(1):354.Texto completo  Resumen

Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 Oct;20(10):1370-85. Resumen

Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 Mar 21;380(12):1116-27.Texto completo  Resumen

Artículos de referencia

1. American Urological Association. Renal mass and localized renal cancer: evaluation, management, and follow up. 2021 [internet publication].Texto completo

2. Mattar K, Jewett MA. Watchful waiting for small renal masses. Curr Urol Rep. 2008 Jan;9(1):22-5. Resumen

3. Jewett MA, Zuniga A. Renal tumor natural history: the rationale and role for active surveillance. Urol Clin North Am. 2008 Nov;35(4):627-34; vii. Resumen

4. Finelli A, Ismaila N, Bro B, et al. Management of small renal masses: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017 Feb 20;35(6):668-80.Texto completo  Resumen

5. Amin MB, Edge S, Green F, et al. AJCC cancer staging manual. 8th ed. (2017). Cham, Switzerland: Springer International; 2017.

6. Brierley JD, Gospodarowicz MK, Wittekind C, eds. Union for International Cancer Control. TNM classification of malignant tumors. 8th ed. Chichester: Wiley-Blackwell; 2017.

7. Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016 Jul;70(1):93-105. Resumen

8. Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013 Oct;37(10):1490-504. Resumen

9. Delahunt B, Eble JN, Egevad L, et al. Grading of renal cell carcinoma. Histopathology. 2019 Jan;74(1):4-17. Resumen

10. Warren AY, Harrison D. WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World J Urol. 2018 Dec;36(12):1913-26.Texto completo  Resumen

11. Shah AY, Karam JA, Malouf GG, et al. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 Dec;120(6):782-92.Texto completo  Resumen

12. Wang KL, Weinrach DM, Luan C, et al. Renal papillary adenoma: a putative precursor of papillary renal cell carcinoma. Hum Pathol. 2007 Feb;38(2):239-46. Resumen

13. Chao DH, Zisman A, Pantuck AJ, et al. Changing concepts in the management of renal oncocytoma. Urology. 2002 May;59(5):635-42. Resumen

14. Lopez-Beltran A, Scarpelli M, Montironi R, et al. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006 May;49(5):798-805. Resumen

15. Davis CJ, Barton JH, Sesterhenn IA, et al. Metanephric adenoma: clinicopathologic study of fifty patients. Am J Surg Pathol. 1995 Oct;19(10):1101-14. Resumen

16. Scott RH, Stiller CA, Walker L, et al. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet. 2006 Sep;43(9):705-15.Texto completo  Resumen

17. Grovas A, Fremgen A, Rauck A, et al. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer. 1997 Dec 15;80(12):2321-32. Resumen

18. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982 Oct;6(7):655-63. Resumen

19. Israel GM, Hindman N, Bosniak MA. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. Radiology. 2004 May;231(2):365-71. Resumen

20. Sevcenco S, Spick C, Helbich TH, et al. Malignancy rates and diagnostic performance of the Bosniak classification for the diagnosis of cystic renal lesions in computed tomography - a systematic review and meta-analysis. Eur Radiol. 2017 Jun;27(6):2239-47.Texto completo  Resumen

21. Agnello F, Albano D, Micci G, et al. CT and MR imaging of cystic renal lesions. Insights Imaging. 2020 Jan 3;11(1):5.Texto completo  Resumen

22. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2019 May;30(5):706-20.Texto completo  Resumen

23. Kawaciuk I, Hyrsl L, Dusek P, et al. Influence of tumour-associated symptoms on the prognosis of patients with renal cell carcinoma. Scand J Urol Nephrol. 2008;42(5):406-11. Resumen

24. European Association of Urology. Renal cell carcinoma. 2021 [internet publication].Texto completo

25. Sacco E, Pinto F, Sasso F, et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int. 2009;83(1):1-11.Texto completo  Resumen

26. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: kidney and renal pelvis cancer. 2021 [internet publication].Texto completo

27. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.Texto completo  Resumen

28. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-49.Texto completo  Resumen

29. Saad AM, Gad MM, Al-Husseini MJ, et al. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: A SEER-based study. Clin Genitourin Cancer. 2019 Feb;17(1):46-57.e5.Texto completo  Resumen

30. Levi F, Ferlay J, Galeone C, et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int. 2008 Apr;101(8):949-58.Texto completo  Resumen

31. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006 Dec;176(6 Pt 1):2353-8. Resumen

32. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019 Jan;75(1):74-84. Resumen

33. Kabaria R, Klaassen Z, Terris MK. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis. 2016 Mar 7;9:45-52.Texto completo  Resumen

34. Macleod LC, Hotaling JM, Wright JL, et al. Risk factors for renal cell carcinoma in the VITAL study. J Urol. 2013 Nov;190(5):1657-61.Texto completo  Resumen

35. Kompotiatis P, Thongprayoon C, Manohar S, et al. Association between urologic malignancies and end-stage renal disease: A meta-analysis. Nephrology (Carlton). 2019 Jan;24(1):65-73. Resumen

36. Chewcharat A, Thongprayoon C, Bathini T, et al. Incidence and mortality of renal cell carcinoma after kidney transplantation: a meta-analysis. J Clin Med. 2019 Apr;8(4):530.Texto completo  Resumen

37. Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol. 2018 Dec;36(12):1891-8.Texto completo  Resumen

38. Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol. 2006 Dec 10;24(35):5593-600. Resumen

39. Ashouri K, Mohseni S, Tourtelot J, et al. Implications of von Hippel-Lindau syndrome and renal cell carcinoma. J Kidney Cancer VHL. 2015 Sep 25;2(4):163-73.Texto completo  Resumen

40. Aghamir SMK, Heshmat R, Ebrahimi M, et al. The impact of succinate dehydrogenase gene (SDH) mutations in renal cell carcinoma (RCC): a systematic review. Onco Targets Ther. 2019 Sep 26;12:7929-40.Texto completo  Resumen

41. Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017 Aug;13(8):496-511. Resumen

42. US Department of Health and Human Services. Smoking cessation: a report of the surgeon general. 2020 [internet publication].Texto completo

43. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438.Texto completo  Resumen

44. Aurilio G, Piva F, Santoni M, et al. The role of obesity in renal cell carcinoma patients: clinical-pathological implications. Int J Mol Sci. 2019 Nov;20(22):5683.Texto completo  Resumen

45. Cumberbatch MG, Rota M, Catto JW, et al. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol. 2016 Sep;70(3):458-66.Texto completo  Resumen

46. Zhang J, Chen Q, Li ZM, et al. Association of body mass index with mortality and postoperative survival in renal cell cancer patients, a meta-analysis. Oncotarget. 2018 Jan 12;9(17):13959-70.Texto completo  Resumen

47. Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008 Feb 15;167(4):438-46.Texto completo  Resumen

48. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 2008 Sep 3;100(17):1260-2.Texto completo  Resumen

49. Zbar B, Glenn G, Merino M, et al. Familial renal cell carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. J Urol. 2007 Feb;177(2):461-5; discussion 465. Resumen

50. Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 2014 Jan;21(1):81-90.Texto completo  Resumen

51. Truong LD, Krishnan B, Cao JT, et al. Renal neoplasm in acquired cystic kidney disease. Am J Kidney Dis. 1995 Jul;26(1):1-12. Resumen

52. Brennan JF, Stilmant MM, Babayan RK, et al. Acquired renal cystic disease: implications for the urologist. Br J Urol. 1991 Apr;67(4):342-8. Resumen

53. McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol. 2000 Apr;27(2):115-23. Resumen

54. Mandel JS, McLaughlin JK, Schlehofer B, et al. International renal-cell cancer study. IV. Occupation. Int J Cancer. 1995;61:601-5. Resumen

55. Kabat GC, Silvera SA, Miller AB, et al. A cohort study of reproductive and hormonal factors and renal cell cancer risk in women. Br J Cancer. 2007 Mar 12; 96(5):845–9.Texto completo  Resumen

56. Lee JE, Hankinson SE, Cho E. Reproductive factors and risk of renal cell cancer: the Nurses' Health Study. Am J Epidemiol. 2009 May 15;169(10):1243-50.Texto completo  Resumen

57. Lindblad P, Mellemgaard A, Schlehofer B, et al. International renal-cell cancer study. V. Reproductive factors, gynecologic operations and exogenous hormones. Int J Cancer. 1995 Apr 10;61(2):192-8. Resumen

58. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6302S-3S.Texto completo  Resumen

59. Rendon RA, Kapoor A, Breau R, et al. Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. Can Urol Assoc J. 2014 May;8(5-6):E398-412.Texto completo  Resumen

60. Leveridge MJ, Bostrom PJ, Koulouris G, et al. Imaging renal cell carcinoma with ultrasonography, CT and MRI. Nat Rev Urol. 2010 Jun;7(6):311-25. Resumen

61. Meister M, Choyke P, Anderson C, et al. Radiological evaluation, management, and surveillance of renal masses in von Hippel-Lindau disease. Clin Radiol. 2009 Jun;64(6):589-600. Resumen

62. Lavallée LT, McAlpine K, Kapoor A, et al. Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer. Can Urol Assoc J. 2019 Dec;13(12):377-83.Texto completo  Resumen

63. Karivedu V, Jain AL, Eluvathingal TJ, et al. Role of positron emission tomography imaging in metabolically active renal cell carcinoma. Curr Urol Rep. 2019 Aug 29;20(10):56. Resumen

64. Pedrosa I, Alsop DC, Rofsky NM. Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer. 2009;115(suppl 10):2334-45. Resumen

65. El-Saeity NS, Sidhu PS. "Scrotal varicocele, exclude a renal tumour": is this evidence based? Clin Radiol. 2006 Jul;61(7):593-9. Resumen

66. Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU guideline. J Urol. 2020 Oct;204(4):778-86.Texto completo  Resumen

67. Dong XQ, Shen Y, Xu LW, et al. Contrast-enhanced ultrasound for detection and diagnosis of renal clear cell carcinoma. Chin Med J (Engl). 2009 May 20;122(10):1179-83. Resumen

68. Heidenreich A, Ravery V. Preoperative imaging in renal cell cancer. World J Urol. 2004 Nov;22(5):307-15. Resumen

69. Silverman SG, Israel GM, Herts BR, et al. Management of the incidental renal mass. Radiology. 2008 Oct;249(1):16-31. Resumen

70. Volpe A. The role of active surveillance of small renal masses. Int J Surg. 2016 Dec;36(pt c):518-24.Texto completo  Resumen

71. Sanchez-Ortiz RF, Madsen LT, Bermejo CE, et al. A renal mass in the setting of a nonrenal malignancy: when is a renal tumor biopsy appropriate? Cancer. 2004 Nov 15;101(10):2195-201.Texto completo  Resumen

72. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001 Mar 15;19(6):1649-57. Resumen

73. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: the SSIGN Score. J Urol. 2002 Dec;168(6):2395-400. Resumen

74. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 1;27(34):5794-9. Resumen

75. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013 Feb;14(2):141-8.Texto completo  Resumen

76. Martini DJ, Liu Y, Shabto JM, et al. Novel risk scoring system for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Oncologist. 2020 Mar;25(3):e484-91.Texto completo  Resumen

77. Peña C, Lathia C, Shan M, et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res. 2010 Oct 1;16(19):4853-63. Resumen

78. Calvo E, Porta C, Grünwald V, et al. The current and evolving landscape of first-line treatments for advanced renal cell carcinoma. Oncologist. 2019 Mar;24(3):338-48.Texto completo  Resumen

79. Rini BI, Battle D, Figlin RA, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019 Dec 20;7(1):354.Texto completo  Resumen

80. Plimack ER, Tannir N, Lin E, et al. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer. 2009 May 1;115(9):1859-66.Texto completo  Resumen

81. de Velasco G, Bex A, Albiges L, et al. Sequencing and combination of systemic therapy in metastatic renal cell carcinoma. Eur Urol Oncol. 2019 Sep;2(5):505-14.Texto completo  Resumen

82. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 Oct;20(10):1370-85. Resumen

83. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 Mar 21;380(12):1116-27.Texto completo  Resumen

84. Quhal F, Mori K, Bruchbacher A, et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol. 2021 Mar 20 [Epub ahead of print].Texto completo  Resumen

85. Pierorazio PM, Johnson MH, Patel HD, et al. Management of renal masses and localized renal cancer: systematic review and meta-analysis. J Urol. 2016 Oct;196(4):989-99.Texto completo  Resumen

86. Crispen PL, Viterbo R, Boorjian SA, et al. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009 Jul 1;115(13):2844-52. Resumen

87. Fan X, Xu K, Lin T, et al. Comparison of transperitoneal and retroperitoneal laparoscopic nephrectomy for renal cell carcinoma: a systematic review and meta-analysis. BJU Int. 2013 Apr;111(4):611-21. Resumen

88. Masson-Lecomte A, Bensalah K, Seringe E, et al. A prospective comparison of surgical and pathological outcomes obtained after robot-assisted or pure laparoscopic partial nephrectomy in moderate to complex renal tumours: results from a French multicentre collaborative study. BJU Int. 2013 Feb;111(2):256-63. Resumen

89. Xia L, Wang X, Xu T, et al. Systematic review and meta-analysis of comparative studies reporting perioperative outcomes of robot-assisted partial nephrectomy versus open partial nephrectomy. J Endourol. 2017 Sep;31(9):893-909. Resumen

90. Weight CJ, Mulders PF, Pantuck AJ, et al. The role of adrenalectomy in renal cancer. Eur Urol Focus. 2016 Feb;1(3):251-57. Resumen

91. Kim SP, Thompson RH, Boorjian SA, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol. 2012 Jul;188(1):51-7. Resumen

92. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011 Apr;59(4):543-52. Resumen

93. Kroon BK, de Bruijn R, Prevoo W, et al. Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. Urology. 2013 Jan;81(1):111-5. Resumen

94. Hatiboglu G, Hohenfellner M, Arslan A, et al. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. Langenbecks Arch Surg. 2017 Jun;402(4):637-44. Resumen

95. Salagierski M, Wojciechowska A, Zając K, et al. The role of ablation and minimally invasive techniques in the management of small renal masses. Eur Urol Oncol. 2018 Oct;1(5):395-402. Resumen

96. Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer. 2008 Nov 15;113(10):2671-80.Texto completo  Resumen

97. Haidar GM, Hicks TD, El-Sayed HF, et al. Treatment options and outcomes for caval thrombectomy and resection for renal cell carcinoma. J Vasc Surg Venous Lymphat Disord. 2017 May;5(3):430-36. Resumen

98. Bai Y, Li S, Jia Z, et al. Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review. Urol Oncol. 2018 Feb;36(2):79.e1-79.e10. Resumen

99. Ravaud A, Motzer RJ, Pandha HS, et al; S-TRAC Investigators. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016 Dec 8;375(23):2246-54.Texto completo  Resumen

100. Schrader AJ, Steffens S, Schnoeller TJ, et al. Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy? Int J Urol. 2012 Oct;19(10):903-7. Resumen

101. Ouzaid I, Capitanio U, Staehler M, et al. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol. 2019 Mar;2(2):141-9. Resumen

102. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 Dec 6;345(23):1655-9.Texto completo  Resumen

103. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001 Sep 22;358(9286):966-70. Resumen

104. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018 Aug 2;379(5):417-27.Texto completo  Resumen

105. Bhindi B, Abel EJ, Albiges L, et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol. 2019 Jan;75(1):111-28. Resumen

106. Kuusk T, Szabados B, Liu WK, et al. Cytoreductive nephrectomy in the current treatment algorithm. Ther Adv Med Oncol. 2019 Sep 27;11:1758835919879026.Texto completo  Resumen

107. Hsiang WR, Kenney PA, Leapman MS. Redefining the Role of surgical management of metastatic renal cell carcinoma. Curr Oncol Rep. 2020 Mar 13;22(4):35. Resumen

108. Hofmann F, Hwang EC, Lam TB, et al. Targeted therapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev. 2020 Oct 14;(10):CD012796.Texto completo  Resumen

109. Powles T; ESMO Guidelines Committee. Recent eUpdate to the ESMO clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Mar;32(3):422-3.Texto completo  Resumen

110. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021 Mar 4;384(9):829-41.Texto completo  Resumen

111. Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021 Apr 8;384(14):1289-300. Resumen

112. Cangiano T, Liao J, Naitoh J, et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999 Feb;17(2):523-8. Resumen

113. Gulati S, Vaishampayan U. Current state of systemic therapies for advanced renal cell carcinoma. Curr Oncol Rep. 2020 Feb 11;22(3):26. Resumen

114. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug 1;27(22):3584-90.Texto completo  Resumen

115. Motzer RJ, Hutson TE, Reeves J, et al. Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the COMPARZ trial. ESMO Congress; October 1, 2012; Vienna. Abstract LBA8.Texto completo

116. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 Aug 22;369(8):722-31.Texto completo  Resumen

117. Escudier BJ, Porta C, Bono P, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310. J Clin Oncol. 2012;30(suppl):abstract CRA4502).Texto completo

118. Basso M, Cassano A, Barone C. A survey of therapy for advanced renal cell carcinoma. Urol Oncol. 2010 Mar-Apr;(2):121-33. Resumen

119. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 1;28(13):2137-43.Texto completo  Resumen

120. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011 Dec 3;378(9807):1931-9. Resumen

121. George DJ, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the alliance A031203 CABOSUN trial. Oncologist. 2019 Nov;24(11):1497-501.Texto completo  Resumen

122. Choueiri TK, Escudier B, Powles T, et al; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917-27. Resumen

123. Martínez Chanzá N, Xie W, Asim Bilen M, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019 Apr;20(4):581-90.Texto completo  Resumen

124. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015 Nov;16(15):1473-82. Resumen

125. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 May 31;356(22):2271-81.Texto completo  Resumen

126. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 9;372(9637):449-56. Resumen

127. National Institute for Health and Care Excellence. Everolimus for advanced renal cell carcinoma after previous treatment. February 2017 [internet publication].Texto completo

128. Motzer RJ, Escudier B, McDermott DF, et al; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13.Texto completo  Resumen

129. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar 21;380(12):1103-1115.Texto completo  Resumen

130. Bajwa R, Cheema A, Khan T, et al. Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res. 2019 Apr;11(4):225-236.Texto completo  Resumen

131. Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020 Jan;21(1):95-104. Resumen

132. Pal SK, Escudier BJ, Atkins MB, et al. Final overall survival results from a phase 3 study to compare tivozanib to sorafenib as third- or fourth-line therapy in subjects with metastatic renal cell carcinoma. Eur Urol. 2020 Dec;78(6):783-5. Resumen

133. Calvo E, Maroto P, del Muro XG, et al. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. Cancer Metastasis Rev. 2010 Aug;29 Suppl 1:11-20. Resumen

134. Hale P, Hahn AW, Rathi N, et al. Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. J Geriatr Oncol. 2019 Jan;10(1):149-54. Resumen

135. Malouf GG, Joseph RW, Shah AY, et al. Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. Clin Adv Hematol Oncol. 2017 May;15(5):409-18. Resumen

136. Fernández-Pello S, Hofmann F, Tahbaz R, et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol. 2017 Mar;71(3):426-36. Resumen

137. Haas NB, Lin X, Manola J, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012 Jun;29(2):761-7.Texto completo  Resumen

138. Keskin SK, Msaouel P, Hess KR, et al. Outcomes of patients with renal cell carcinoma and sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies: comparison between the cytokine and targeted therapy eras. J Urol. 2017 Sep;198(3):530-37.Texto completo  Resumen

139. Tunio MA, Hashmi A, Rafi M. Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials. Ann Oncol. 2010 Sep;21(9):1839-45.Texto completo  Resumen

140. Siva S, Kothari G, Muacevic A, et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol. 2017 Sep;14(9):549-63. Resumen

141. Zaorsky NG, Lehrer EJ, Kothari G, et al. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019 Sep;2(5):515-23.Texto completo  Resumen

142. Kothari G, Foroudi F, Gill S, et al. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 2015 Feb;54(2):148-57.Texto completo  Resumen

143. He L, Liu Y, Han H, et al. Survival outcomes after adding stereotactic body radiotherapy to metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Am J Clin Oncol. 2020 Jan;43(1):58-63.Texto completo  Resumen

144. Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev. 2008 Apr;34(2):183-92. Resumen

145. ClinicalTrials.gov. A phase 2 study of belzutifan (PT2977, MK-6482) for the treatment of von Hippel Lindau (VHL) disease-associated renal cell carcinoma (RCC) (MK-6482-004). August 2021 [internet publication].Texto completo

146. Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Mar;15(3):286-96.Texto completo  Resumen

147. Hah YS, Koo KC. Immunology and immunotherapeutic approaches for advanced renal cell carcinoma: a comprehensive review. Int J Mol Sci. 2021 Apr 24;22(9):4452.Texto completo  Resumen

148. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 Jun 15;393(10189):2404-15. Resumen

149. Kuusk T, Abu-Ghanem Y, Mumtaz F, et al. Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. Curr Opin Urol. 2021 May 1;31(3):262-9. Resumen

150. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021 Aug 19;385(8):683-94. Resumen

151. Jung KH, LoRusso P, Burris H, et al. Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 Inhibitor (atezolizumab) in advanced solid tumors. Clin Cancer Res. 2019 Jun 1;25(11):3220-28. Resumen

152. Wegner RE, Abel S, Vemana G, et al. Utilization of stereotactic ablative body radiation therapy for intact renal cell carcinoma: trends in treatment and predictors of outcome. Adv Radiat Oncol. 2020 Jan-Feb;5(1):85-91.Texto completo  Resumen

153. Siva S, Louie AV, Warner A, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer. 2018 Mar 1;124(5):934-42. Resumen

154. Correa RJM, Louie AV, Zaorsky NG, et al. The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis. Eur Urol Focus. 2019 Nov;5(6):958-69.Texto completo  Resumen

155. Ritchie RW, Leslie T, Phillips R, et al. Extracorporeal high intensity focused ultrasound for renal tumours: a 3-year follow-up. BJU Int. 2010 Oct;106(7):1004-9.Texto completo  Resumen

156. Ritchie RW, Leslie TA, Turner GD, et al. Laparoscopic high-intensity focused ultrasound for renal tumours: a proof of concept study. BJU Int. 2011 Apr;107(8):1290-6.Texto completo  Resumen

157. Draube A, Klein-González N, Mattheus S, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE. 2011 Apr 20;6(4):e18801.Texto completo  Resumen

158. Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017 Jan;27(1):74-95.Texto completo  Resumen

159. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004 Feb 21;363(9409):594-9. Resumen

160. Koster BD, Santegoets SJAM, Harting J, et al. Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial. Cancer Immunol Immunother. 2019 Jun;68(6):1025-35.Texto completo  Resumen

161. Donat SM, Diaz M, Bishoff JT, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol. 2013 Aug;190(2):407-16.Texto completo  Resumen

162. Dabestani S, Marconi L, Kuusk T, et al. Follow-up after curative treatment of localised renal cell carcinoma. World J Urol. 2018 Dec;36(12):1953-59. Resumen

163. Bazzi WM, Sjoberg DD, Feuerstein MA, et al. Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience. J Urol. 2015 Jun;193(6):1911-6.Texto completo  Resumen

164. Gangadaran SGD. Current management options in metastatic renal cell cancer. Oncol Rev. 2017 Jun 14;11(2):339.Texto completo  Resumen

165. Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer. 2009 Feb 15;115(4):776-83.Texto completo  Resumen

166. Garje R, An J, Greco A, et al. The future of immunotherapy-based combination therapy in metastatic renal cell carcinoma. Cancers (Basel). 2020 Jan 7;12(1):143.Texto completo  Resumen

167. Hofmann HS, Neef H, Krohe K, et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005 Jul;48(1):77-81. Resumen

168. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998 Jun;16(6):2261-6. Resumen

169. Piltz S, Meimarakis G, Wichmann MW, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg. 2002 Apr;73(4):1082-7. Resumen

170. Alasker A, Meskawi M, Sun M, et al. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Cancer Treat Rev. 2013 Jun;39(4):388-401. Resumen

171. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul;28 Suppl 4:iv119-42. Resumen

172. Williamson TJ, Pearson JR, Ischia J, et al. Guideline of guidelines: follow-up after nephrectomy for renal cell carcinoma. BJU Int. 2016 Apr;117(4):555-62.Texto completo  Resumen

173. Skolarikos A, Alivizatos G, Laguna P, et al. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol. 2007 Jun;51(6):1490-500. Resumen

174. Canadian Kidney Cancer Forum. Management of kidney cancer: Canadian Kidney Cancer Forum consensus update. Can Urol Assoc J. 2009 Jun;3(3):200-4.Texto completo  Resumen

175. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008 May;53(5):917-30. Resumen

176. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007 Jan 3;99(1):81-3.Texto completo  Resumen

177. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007 Apr;17(4):351-5. Resumen

178. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009 Apr;6(4):219-28.Texto completo  Resumen

179. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with the tyrosine kinase inhibitor sunitinib. Lancet. 2007 Dec 15;370(9604):2011-9.Texto completo  Resumen

180. Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009 Sep;20(9):1535-42.Texto completo  Resumen

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad